Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Cognition Therapeutics (CGTX) News Today

Cognition Therapeutics logo
$1.99 -0.03 (-1.49%)
Closing price 08/21/2025 04:00 PM Eastern
Extended Trading
$2.00 +0.01 (+0.75%)
As of 08:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

CGTX Latest News

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Update
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cognition-therapeutics-inc-nasdaqcgtx-short-interest-update-2025-08-20/
What is HC Wainwright's Estimate for CGTX FY2025 Earnings?
August 16, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-estimate-for-cgtx-fy2025-earnings-2025-08-14/
Cognition Therapeutics Reports Q2 2025 Financial Results
August 15, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/cognition-therapeutics-reports-q2-2025-financial-results/ar-AA1KzmK4
Equities Analysts Issue Forecasts for CGTX FY2025 Earnings
August 15, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30277587
Cognition Therapeutics Shares Surge After FDA Confirms Phase 3 Trial Design
August 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/cognition-therapeutics-shares-surge-after-fda-confirms-phase-3-trial-design/ar-AA1KsvTm
Cognition Therapeutics confirms aligment with FDA on path for zervimesine
August 12, 2025  |  msn.comhttps://www.msn.com/en-us/science/biochemistry/cognition-therapeutics-confirms-aligment-with-fda-on-path-for-zervimesine/ar-AA1Kpt9K
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease
August 12, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/12/3132086/0/en/cognition-therapeutics-receives-end-of-phase-2-meeting-minutes-confirming-alignment-with-u-s-fda-on-registrational-path-for-zervimesine-ct1812-in-alzheimer-s-disease.html
Cognition Therapeutics' (CGTX) "Buy" Rating Reiterated at Chardan Capital
August 11, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30269122
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs
August 8, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CGTX/pressreleases/33974326/cognition-therapeutics-reports-financial-results-for-the-second-quarter-2025-and-highlights-progress-across-clinical-programs/
Cognition (CGTX) Q2 Grant Income Jumps
August 8, 2025  |  fool.comhttps://www.fool.com/data-news/2025/08/08/cognition-cgtx-q2-grant-income-jumps/
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
July 30, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/cognition-therapeutics-presents-data-aaic-113000568.html
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease
July 29, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/29/3123138/0/en/cognition-therapeutics-presents-data-at-aaic-highlighting-broad-neurological-impact-of-zervimesine-ct1812-in-dementia-with-lewy-bodies-and-alzheimer-s-disease.html
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease
July 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/21/3118639/0/en/cognition-therapeutics-publishes-proteomic-analysis-elucidating-zervimesine-s-protection-of-neurons-and-synapses-in-alzheimer-s-disease.html
Cognition Therapeutics stock soars after DLB study results
July 16, 2025  |  in.investing.comhttps://in.investing.com/news/stock-market-news/cognition-therapeutics-stock-soars-after-dlb-study-results-93CH-4914251
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
July 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/16/3116291/0/en/cognition-therapeutics-positive-clinical-data-from-zervimesine-ct1812-phase-2-study-in-dementia-with-lewy-bodies-dlb-will-be-presented-in-a-podium-presentation-at-aaic.html
Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress
July 11, 2025  |  insidermonkey.comhttps://www.insidermonkey.com/blog/cognition-therapeutics-inc-cgtx-retains-buy-rating-on-start-study-progress-1566255/
Cognition Therapeutics, Inc.: Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease
July 11, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-07/65877275-cognition-therapeutics-inc-cognition-therapeutics-completes-end-of-phase-2-meeting-with-fda-for-zervimesine-ct1812-in-alzheimer-s-disease-399.htm
Cognition Therapeutics Shares Jump 75% After FDA Discussion on Alzheimer’s Treatment
July 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/medical/cognition-therapeutics-shares-jump-75-after-fda-discussion-on-alzheimer-s-treatment/ar-AA1IlMja
Cognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesine
July 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/medical/cognition-soars-35-after-positive-fda-meeting-on-alzheimer-s-asset-zervimesine/ar-AA1ImAX6
Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug
July 10, 2025  |  in.investing.comhttps://in.investing.com/news/stock-market-news/cognition-therapeutics-stock-soars-after-fda-meeting-on-alzheimers-drug-93CH-4907058
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease
July 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/cognition-therapeutics-completes-end-phase-113000554.html
Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA
July 10, 2025  |  quiverquant.comQ
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease
July 10, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/10/3113149/0/en/cognition-therapeutics-completes-end-of-phase-2-meeting-with-fda-for-zervimesine-ct1812-in-alzheimer-s-disease.html
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data
July 5, 2025  |  benzinga.comhttps://www.benzinga.com/markets/equities/25/07/46258444/cognition-therapeutics-shares-jump-12-after-hours-following-encouraging-phase-2-alzheimers-trial
CGTX - Cognition Therapeutics Inc Executives - Morningstar
July 3, 2025  |  morningstar.comM
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
July 1, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/cognition-therapeutics-study-zervimesine-ct1812-113000952.html
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target
July 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/01/3108233/0/en/cognition-therapeutics-study-of-zervimesine-ct1812-in-early-alzheimer-s-disease-surpasses-50-enrollment-target.html
Cognition Therapeutics, Inc. (CGTX) - Yahoo Finance
June 30, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/CGTX/financials/
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
June 25, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/cognition-therapeutics-provides-regulatory-zervimesine-113000722.html
Cognition Therapeutics, Inc. Schedules End-of-Phase 2 Meeting with FDA for Alzheimer's Treatment and Files Applications for Breakthrough Status in Dementia with Lewy Bodies
June 25, 2025  |  quiverquant.comQ
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)
June 25, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/25/3104986/0/en/cognition-therapeutics-provides-regulatory-update-on-zervimesine-ct1812-in-alzheimer-s-disease-and-dementia-with-lewy-bodies-dlb.html
Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
June 3, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/philanthropic-donor-funds-cognition-therapeutics-113000270.html
Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
June 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/03/3092639/0/en/philanthropic-donor-funds-cognition-therapeutics-expanded-access-program-for-zervimesine-ct1812-in-dementia-with-lewy-bodies.html
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies
May 28, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/28/3089354/0/en/cognition-therapeutics-releases-new-episode-of-conversations-podcast-studying-the-patient-caregiver-lived-experience-in-dementia-with-lewy-bodies.html
Cognition announces outcomes from trial of zervimesine for geographic atrophy
May 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/cognition-announces-outcomes-trial-zervimesine-153134382.html?fr=sycsrp_catchall
Cognition Therapeutics presents preclinical data on zervimesine at ARVO
May 9, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/cognition-therapeutics-presents-preclinical-data-on-zervimesine-at-arvo/ar-AA1EtFit
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
May 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/09/3078151/0/en/cognition-therapeutics-presented-data-at-association-for-research-in-vision-and-ophthalmology-showing-impact-on-retinal-cell-health.html
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
May 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/cognition-therapeutics-reports-topline-results-113000156.html
Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
May 7, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65328776-cognition-therapeutics-inc-cognition-therapeutics-reports-financial-results-for-the-first-quarter-2025-and-provides-business-update-399.htm
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
May 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/07/3075995/0/en/cognition-therapeutics-reports-financial-results-for-the-first-quarter-2025-and-provides-business-update.html
Cognition Therapeutics presents results at AD/PD 2025 on CT1812
April 2, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cognition-therapeutics-presents-results-at-ad-pd-2025-on-ct1812-1034538156
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
April 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cognition-therapeutics-presents-results-at-ad-pd-2025-showing-impact-of-zervimesine-ct1812-on-alzheimer-s-disease-processes-1034536165
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes
April 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/01/3053217/0/en/cognition-therapeutics-presents-results-at-ad-pd-2025-showing-impact-of-zervimesine-ct1812-on-alzheimer-s-disease-processes.html
Cognition to Reveal Biomarker Findings Next Week
March 25, 2025  |  baystreet.cahttps://www.baystreet.ca/articles/stockstowatch/109911/Cognition-to-Reveal-Biomarker-Findings-Next-Week
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025
March 25, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/25/3048620/0/en/cognition-therapeutics-to-report-biomarker-results-from-phase-2-shine-study-in-mild-to-moderate-alzheimer-s-disease-in-podium-presentation-at-ad-pd-2025.html
Cognition Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
March 24, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cognition-therapeutics-price-target-lowered-to-5-from-6-at-h-c-wainwright-1034508305
Earnings call transcript: Cognition Therapeutics Q4 2024 sees $34M net loss
March 22, 2025  |  uk.investing.comhttps://uk.investing.com/news/transcripts/earnings-call-transcript-cognition-therapeutics-q4-2024-sees-34m-net-loss-93CH-3989049
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript
March 22, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/cognition-therapeutics-inc-nasdaq-cgtx-q4-2024-earnings-call-transcript/ar-AA1BrB7X
Cognition Therapeutics price target lowered to $8 from $11 at Chardan
March 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cognition-therapeutics-price-target-lowered-to-8-from-11-at-chardan-1034503384
Cognition Therapeutics Earnings Call: Progress Amid Challenges
March 21, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cognition-therapeutics-earnings-call-progress-amid-challenges?utm_source=marketbeat.com&utm_medium=referral
Get Cognition Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.

CGTX Media Mentions By Week

CGTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CGTX
News Sentiment
▼
0.92

0.54
▲
Average
Medical
News Sentiment

CGTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CGTX Articles
This Week
▼
4

2
▲
CGTX Articles
Average Week

Get Cognition Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:CGTX) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners
Silver’s Still Under $35… For Now.
Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...
GoldenCrest Metals | Sponsoredtc pixel
One tiny company just cracked Google’s $19B problem
Google’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...
True Market Insiders | Sponsoredtc pixel
What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...
Reagan Gold Group | Sponsoredtc pixel
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsoredtc pixel
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsoredtc pixel
US attacks China, September 30?
The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...
Stansberry Research | Sponsoredtc pixel
I trusted Trump and got screwed
Porter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...
Porter & Company | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel